JP2024538721A - Gabaa受容体活性を有するフラボノイド誘導体および使用方法 - Google Patents

Gabaa受容体活性を有するフラボノイド誘導体および使用方法 Download PDF

Info

Publication number
JP2024538721A
JP2024538721A JP2024521052A JP2024521052A JP2024538721A JP 2024538721 A JP2024538721 A JP 2024538721A JP 2024521052 A JP2024521052 A JP 2024521052A JP 2024521052 A JP2024521052 A JP 2024521052A JP 2024538721 A JP2024538721 A JP 2024538721A
Authority
JP
Japan
Prior art keywords
compound
bond
group
occurrence
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024521052A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538721A5 (cg-RX-API-DMAC7.html
Inventor
アイリーン キャリー
ジェイムズ イー. サイモン
ジャックス ロバージ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers, The State University of New Jersey
Original Assignee
Rutgers, The State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers, The State University of New Jersey filed Critical Rutgers, The State University of New Jersey
Publication of JP2024538721A publication Critical patent/JP2024538721A/ja
Publication of JP2024538721A5 publication Critical patent/JP2024538721A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
    • C07D265/22—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/32—2,3-Dihydro derivatives, e.g. flavanones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024521052A 2021-10-07 2022-10-06 Gabaa受容体活性を有するフラボノイド誘導体および使用方法 Pending JP2024538721A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163253341P 2021-10-07 2021-10-07
US63/253,341 2021-10-07
PCT/US2022/045904 WO2023059802A1 (en) 2021-10-07 2022-10-06 Flavonoid derivatives with gabaa receptor activity and methods of use

Publications (2)

Publication Number Publication Date
JP2024538721A true JP2024538721A (ja) 2024-10-23
JP2024538721A5 JP2024538721A5 (cg-RX-API-DMAC7.html) 2025-09-30

Family

ID=85803715

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024521052A Pending JP2024538721A (ja) 2021-10-07 2022-10-06 Gabaa受容体活性を有するフラボノイド誘導体および使用方法

Country Status (7)

Country Link
US (1) US20240398821A1 (cg-RX-API-DMAC7.html)
EP (1) EP4412605A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024538721A (cg-RX-API-DMAC7.html)
CN (1) CN118354770A (cg-RX-API-DMAC7.html)
AU (1) AU2022361421A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233822A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023059802A1 (cg-RX-API-DMAC7.html)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5251378A (en) * 1975-10-20 1977-04-25 Chugai Pharmaceut Co Ltd Preparation of 4(3h)-quinazolinone derivatives
JPH07506386A (ja) * 1992-04-27 1995-07-13 フロリダ・ステート・ユニバーシティー 低自己吸収性の固有にシンチレートするポリマー
JP2000505055A (ja) * 1995-10-17 2000-04-25 ユニバーシティ オブ ストラスクライド 不安の治療に対するニトロフラボノイドの使用
WO2001083456A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
JP2002504481A (ja) * 1998-02-18 2002-02-12 ニューロサーチ、アクティーゼルスカブ 新規化合物及び陽性ampaレセプターモジュレーターとしてこれを使用する方法
WO2006045010A2 (en) * 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
JP2013536238A (ja) * 2010-08-24 2013-09-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ジヒドロミリセチンの投与を含む、アルコール中毒、アルコール使用障害およびアルコール乱用の治療方法
CN106478525A (zh) * 2015-08-28 2017-03-08 南京理工大学 一种合成喹唑酮的方法
CN109879820A (zh) * 2019-02-26 2019-06-14 扬州大学 一种喹唑啉酮杂环化合物的合成方法

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5251378A (en) * 1975-10-20 1977-04-25 Chugai Pharmaceut Co Ltd Preparation of 4(3h)-quinazolinone derivatives
JPH07506386A (ja) * 1992-04-27 1995-07-13 フロリダ・ステート・ユニバーシティー 低自己吸収性の固有にシンチレートするポリマー
JP2000505055A (ja) * 1995-10-17 2000-04-25 ユニバーシティ オブ ストラスクライド 不安の治療に対するニトロフラボノイドの使用
JP2002504481A (ja) * 1998-02-18 2002-02-12 ニューロサーチ、アクティーゼルスカブ 新規化合物及び陽性ampaレセプターモジュレーターとしてこれを使用する方法
WO2001083456A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
WO2006045010A2 (en) * 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
JP2013536238A (ja) * 2010-08-24 2013-09-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ジヒドロミリセチンの投与を含む、アルコール中毒、アルコール使用障害およびアルコール乱用の治療方法
CN106478525A (zh) * 2015-08-28 2017-03-08 南京理工大学 一种合成喹唑酮的方法
CN109879820A (zh) * 2019-02-26 2019-06-14 扬州大学 一种喹唑啉酮杂环化合物的合成方法

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ELISA OGNIBENE, ET AL.: "Behavioral effects of 6-bromoflavanone and 5-methoxy-6,8-dibromoflavanone as anxiolytic compounds", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol. 32(1), JPN7026003368, 2008, pages 128 - 134, ISSN: 0005920291 *
GYORGY LITKEI, ET AL.: "Hydroxymethylation of flavanones", ORG. PREP. PROC. INT., vol. 23(6), JPN7026003366, 1991, pages 741 - 747, ISSN: 0005920289 *
HARRY L. YALE AND MARION KALKSTEIN: "Substituted 2,3-Dihydro-4(1H)-quinazolinones. A New Class of Inhibitors of Cell Multiplication", J. MED. CHEM, vol. 10(2), JPN7026003373, 1967, pages 334 - 336, ISSN: 0005920296 *
LIHUAN REN, ET AL.: "Effects of flavone 6-substitutions on GABAA receptors efficacy", ERU. J. PHARM., vol. 670(1), JPN7026003370, 2011, pages 121 - 129, ISSN: 0005920293 *
MARIEL MARDER, ET AL.: "Molecular modeling and QSAR analysis of the interaction of flavone derivatives with the benzodiazepi", BIOORG. MED. CHEM., vol. 9(2), JPN7026003371, 2001, pages 323 - 335, ISSN: 0005920294 *
MICHAEL S.Y. HUEN, ET AL.: "Naturally occurring 20-hydroxyl-substituted flavonoids as high-affinitybenzodiazepine site ligands", BIOCHEM. PHARM., vol. 66(12), JPN7026003367, 2003, pages 2397 - 2407, ISSN: 0005920290 *
SHWETA MISHRA, ET AL.: "Electronegativity in Substituted-4(H)-quinazolinones Causes Anxiolysis without a Sedative-hypnotic A", CENTRAL NERVOUS SYSTEM AGENTS IN MEDICINAL CHEMISTRY, vol. 20(1), JPN7026003372, 2020, pages 26 - 40, ISSN: 0005920295 *
SOMEPALLI VENKATESWARLU, ET AL.: "Fused Quinazolinoquinazolinones: Synthesis, Isomerization, Spectroscopic Identification, and Antican", J.HETEROCYC.CHEM., vol. 52(6), JPN7026003374, 2015, pages 1631 - 1638, ISSN: 0005920297 *
WON-JEA CHO, ET AL.: "Synthesis and biological evaluation of 3-arylisoquinolines as antitumor agents", BIOORG. MED. CHEM., vol. 8(1), JPN7026003375, 1998, pages 41 - 46, ISSN: 0005920298 *
XIAOQIN HUANG, ET AL.: "3D-QSAR Model of Flavonoids Binding at Benzodiazepine Site in GABAAReceptors", J. MED. CHEM., vol. 44(12), JPN7026003369, 2001, pages 1883 - 1891, ISSN: 0005920292 *

Also Published As

Publication number Publication date
EP4412605A4 (en) 2025-07-30
CN118354770A (zh) 2024-07-16
CA3233822A1 (en) 2023-04-13
US20240398821A1 (en) 2024-12-05
EP4412605A1 (en) 2024-08-14
AU2022361421A1 (en) 2024-05-09
WO2023059802A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
RU2449996C2 (ru) СОЕДИНЕНИЯ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЗАИМОДЕЙСТВИЯ БЕЛКОВ Bcl С ПАРТНЕРАМИ СВЯЗЫВАНИЯ
US20230365542A1 (en) Selective Agonists of 5-HT2A Receptor and Methods of Use
CN101006065B (zh) 抑制bcl蛋白与结合伴侣的相互作用的化合物和方法
WO2024010585A1 (en) Non-covalent inhibitors of the main protease of sars-cov-2 and methods of use
TW201940487A (zh) sGC刺激劑之晶型
CN101374807B (zh) 用于抑制bcl蛋白与结合配偶体的相互作用的化合物和方法
US20240398821A1 (en) Flavonoid derivatives with gabaa receptor activity and methods of use
CN102046163A (zh) 使用乌地那非(udenafil)与阿呋唑嗪(alfuzosin)或奥昔布宁(oxybutynin)组合治疗膀胱过度活动症
AU2003267557B2 (en) Treatment of dyskinesia
WO2022162193A1 (en) Methods for the treatment of childhood-onset fluency disorder
WO2025217596A1 (en) Substituted 2,3-dihydro-4h-benzo[e][ 1,3] oxazin-4-one compounds and methods of use thereof
HK40115276A (en) Flavonoid derivatives with gabaa receptor activity and methods of use
US20220388980A1 (en) Quinoline inhibitors of rad52 and methods of use
WO2025217249A1 (en) Methods for treating endometriosis and/or other ovary-related diseases and for monitoring treatment
JP2004300147A (ja) 受容体拮抗剤
KR20250129797A (ko) 글루코오스 수치를 조절하기 위한 조성물 및 방법
WO2021046789A1 (zh) 吲唑-甲酰胺衍生物及其用途
EP1815854A1 (en) Treatment of dyskenesia
HK1105963B (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
CA2991236A1 (en) Therapeutic compounds and compositions for treating social disorders and substance use disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250919

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250919

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260626

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260730

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260807